• William S Bradham, Susan P Bell, Douglas W Adkisson, Holly M Smith, Frank E Harrell, Mark A Lawson, Henry Ooi, Douglas B Sawyer, and Marvin W Kronenberg.
• Division of Cardiovascular Medicine and Department of Biostatistics, Vanderbilt University School of Medicine and the Cardiology Section, Veterans Administration Tennessee Valley Healthcare System, Nashville, Tennessee.
• J. Card. Fail. 2017 Mar 1; 23 (3): 262-265.

BackgroundThe myocardial longitudinal relaxation time (T1) on cardiac magnetic resonance imaging (CMR) can quantify myocardial fibrosis in the presence or absence of visually detectable late gadolinium (Gd) enhancement (LGE). Mineralocorticoid receptor antagonist (MRA) treatment produces beneficial remodeling in nonischemic dilated cardiomyopathy (NIDCM). We assessed the hypothesis that interstitial myocardial fibrosis measured with the use of CMR predicts left ventricular (LV) beneficial remodeling in NIDCM after heart failure (HF) treatment including MRAs.Methods And ResultsTwelve patients with NIDCM, on stable beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor-blocking therapy, were studied before and after 6-29 months of treatment with MRAs, by means of CMR assessment of LV structure, function, and T1 from standard Look-Locker sequences (T1LL). All patients had depressed cardiac function, dilated left ventricles, and no visual LGE. After adding MRA to HF treatment, the LV ejection fraction increased and the LV end-systolic volume index (LV end-systolic volume/m2) decreased in all patients (P < .0001). This this was inversely proportional to the baseline myocardial T1LL (r = -0.65; P = .02).ConclusionMyocardial T1LL, in the absence of visually detectable LGE, was quantitatively related to the degree of beneficial LV remodeling achieved in response to adding MRA to a HF regimen.Published by Elsevier Inc.

27 keywords...

hide…